| Outcome Measures: |
Primary: Capillary blood glucose levels as baseline corrected AUC: AUCbaseline_c (0-180 minutes) [Baseline corrected area under curve from 0 to 180 minutes for blood glucose concentration (= Area under curve from 0 to 180 minutes minus baseline*180 minutes)], 0 - 180 minutes, during 4 study visits | Secondary: Maximum blood glucose concentration (Cmax), 0 - 180 minutes, during 4 study visits|Maximum increase of blood glucose concentration (Max_increase), 0 - 180 minutes, during 4 study visits|Relative maximum increase of blood glucose concentration (Max_increase_rel), 0 - 180 minutes, during 4 study visits|Time to reach maximum blood glucose concentration (Tmax), 0 - 180 minutes, during 4 study visits|Total area under curve from 0 to 180 minutes for blood glucose concentration (AUC(0-180 minutes)), 0 - 180 minutes, during 4 study visits|Incremental area under curve from 0 to 180 minutes for blood glucose concentration, i.e., above baseline levels for blood glucose concentration after oral intake of Laevolac crystals/liquid or control products (iAUC(0-180min)), 0 - 180 minutes, during 4 study visits | Other: Adverse Events (AEs), Adverse Events will be documented from start of fasting on the day before Screening until the day after the last study Intervention. This is up to 64 days, depending on the day of Screening (21 to 3 days before the first study Intervention) and on the duration of wash out phases between interventions., up to 64 days|Gastrointestinal tolerability: global scaled evaluation, Gastrointestinal tolerability will be assessed by the patients by means of a global scaled evaluation with "Very good", "Good", "Moderate", or "Poor"., 180 minutes and 24 hours post-dose|Gastrointestinal tolerability: diarrhoea, distension, rumbling, nausea, vomiting, burping, regurgitation/heartburn, flatulence, abdominal discomfort, abdominal pain, The single gastrointestinal symptoms will be assessed by the patients using a 4-point Likert scale: "No symptoms or discomfort", "Mild symptoms or discomfort", "Moderate symptoms of discomfort", or "Severe symptoms of discomfort"., 180 minutes and 24 hours post-dose|Blood glucose concentration at 240 minutes - only when blood glucose is >10 mmol/L (>180 mg/dL) at 180 minutes, 240 minutes post-dose
|
